BridgeBio Pharma's Stock Surge Amid Drug Development Success

Shares of BridgeBio Pharma, ticker BBIO, have surged over 160 percent in 2025, as the company competes with industry giants Pfizer and Alnylam Pharmaceuticals. BridgeBio, founded just a decade ago, has made a significant impact with its approved drug, Attruby, which targets transthyretin amyloid cardiomyopathy, or ATTR-CM.

This condition leads to abnormal protein accumulation in the heart, resulting in damage. Attruby competes directly with Pfizer's Vyndaqel and Alnylam's Amvuttra. Notably, BridgeBio's market capitalization is four times smaller than Alnylam's and ten times smaller than Pfizer's.

However, sales for Attruby are on the rise, generating $108.1 million in its fourth quarter on the market, a 51 percent increase sequentially, exceeding expectations of $98.2 million. BridgeBio's CEO, Neil Kumar, emphasized the importance of proving their drug's commercial viability in a competitive landscape.

Investors have shown renewed confidence following the company's success in drug commercialization. BridgeBio has also achieved promising results in two late-stage studies for treatments targeting rare genetic diseases.

One of these is BBP-418, aimed at limb girdle muscular dystrophy, or LGMD. This condition is characterized by progressive muscle weakness due to abnormal protein production. The data showed that after three months of treatment, patients experienced a 1.8 times increase in the deficient protein, along with significant functional benefits.

Analyst Tyler Van Buren from Cowen indicated that approval for BBP-418 is likely, projecting it as a billion-dollar opportunity for BridgeBio. The FDA had previously indicated that the drug only needed to demonstrate a trend of functional benefit.

Furthermore, on October 29, BridgeBio announced positive results for its drug encaleret, targeting autosomal dominant hypocalcemia type 1, or ADH1. In this case, 76 percent of patients treated with encaleret achieved normal calcium levels after 24 weeks, compared to just 4 percent of those receiving standard treatment.

The market for ADH1 is reportedly small, with approximately 3,000 to 5,000 diagnosed patients, but potential growth is anticipated through genetic testing and revised treatment guidelines. In addition, BridgeBio is preparing for another Phase 3 study with infigratinib, targeting achondroplasia, the most common form of dwarfism.

This drug could potentially become the only oral treatment for this condition, with Kumar stating that it shows double the efficacy compared to existing injectable treatments. The report cites that while BridgeBio's stock has performed well, analysts are optimistic about its future, with projected sales of BBP-418 and infigratinib exceeding one billion dollars each.

As BridgeBio forges ahead with its R&D initiatives and pipeline, the company aims to continue proving its worth in a competitive biotech landscape, as stated in the Investor's Business Daily report.